Again, the intervention of Leucine-rich alpha-2 glycoprotein (LRG), a serum biomarker for inflammation in IBD, has shown greater accuracy than CRP in assessing clinical and endoscopic disease activity in UC, suggesting it may be a more reliable marker for inflammation in IBD (199–201). Here, LRG1 is linked to inflammatory bowel disease.